The Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SH-1028

Phase 1

• Conditions: Healthy Male Volunteers
• Interventions: Drug: SH-1028; Drug: Itraconazole; Drug: Rifampicin

• Registration Number: NCT04808648
• Lead Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.

Brief Summary

This is a phase I study to assess the drug-drug interaction of SH-1028 tablets and Itraconazole/Rifampicin tablets. The study also evaluates the pharmacokinetic and tolerability of SH-1028 tablets in healthy subjects. This study provides evidence for the designing of following clinical trial protocols.

Detailed Description

A total of 40 evaluable healthy male subjects will be enrolled in this study.The subjects will be divided into two groups, A and B, with 20 people in each group.

In the itraconazole study (Group A), patients received single-dose SH-1028 200 mg on Days 1 and 12 and itraconazole(200 mg twice daily) on Days 8-14 orally.

In the rifampicin study (Group B), patients received SH-1028 200mg once daily on Days 1 and 14 and rifampicin 600 mg once daily on Days 8-16.

Study Timeline

• Status Verified: 2021-03
• Study First Submitted: 2021-03-18
• Study First Submitted QC: 2021-03-18
• Last Update Submitted: 2021-03-18
• Study First Posted: 2021-03-22
• Last Update Posted: 2021-03-22
• Study Start: 2021-04-06
• Primary Completion: 2021-06-10
• Study Completion: 2021-06-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Male
• Target Recruitment: 40

Inclusion Criteria

1. Healthy male volunteers between the age of 18 to 45 years old (including 18 and 45 years old)
2. Body weight between 50.0 and 80.0 kg, Body mass index between 19.0 and 26.0 kg/m2 (including 19.0 and 26.0 kg/m2);
3. Normal physical findings, clinical laboratory values, vital signs and 12-lead ECG, or any abnormality that is non-clinically significant;
4. Promise not to smoke, drink alcohol or drink caffeinated beverages during the trial;
5. Be able to communicate well with the researcher and be able to complete the trial in accordance with the program.
6. Male subjects of reproductive potential with partners will be instructed to,and must be willing to practice a highly effective method of birth control for the duration of the study and continuing 6 months after discontinuing treatment with the investigational product.

Exclusion Criteria

1. History of or current clinically significant cardio, pulmonary, endocrine, metabolism, renal, hepatic, gastrointestinal, dermatology, infection, hematology, neurological, mental disease or disorder. Or any other disease or physiological condition that may affect the results of the study;
2. Those who have undergone surgery within the first 3 months of the screening period, or who plan to undergo surgery during the study period, or who have previously undergone surgery that may affect drug absorption, distribution, metabolism, and excretion;
3. Subjects with dysphagia or have history of gastrointestinal disorders which affects study drug absorption;
4. Alcohol breath test results greater than 0.0mg/100mL.
5. Urine drug screening (morphine, methamphetamine, ketamine, dimethyldioxyamphetamine, tetrahydrocannabinol) positive;
6. Those who had received the vaccine within 28 days prior to screening, or who planned to receive the vaccine during the trial;
7. Positive test for HBs-Ag, HCV-Ab, HIV-Ab, or syphilis antibody;
8. Allergies, have allergies to drugs or foods; or have known allergies to the components of the investigated drug;
9. Those who smoked daily >5 sticks of cigarette, or the weekly alcohol consumption was higher than 14 units of alcohol (1 unit=10ml or 8g absolute alcohol. 25 ml 40% liquor, 330ml 5% beers, 175ml 12% grape wine are equal to 1.0, 1.5 and 2.0 units of alcohol respectively), or the history of drug abuse and drug abuseor 3 months prior to screening period;
10. Subjects with history of blood donation or massive blood loss (> 200 mL) within 3 months prior to screening;
11. Participated in other clinical trials within 3 months before screening;
12. Use of any drugs that alter liver enzyme activity within 28 days prior to screening;
13. Do not promise not to smoke, not drink alcoholic food or beverages, not consume xanthine-rich foods, not consume grapefruit, dragon fruit, mango, lime, carambola or other products within 24 hours before taking the study drug. Prepared foods or beverages, as well as chocolate, tea, coffee or cola and other special diets that affect the absorption, distribution, metabolism and excretion of drugs;
14. People who have used any medicine (including Chinese herbal medicine and health care products) within two weeks before taking the test drug;
15. History of syncope / needle syncope and intolerable intravenous indwelling needle;
16. Those who have special requirements for diet and cannot follow a unified diet;
17. hose who cannot complete this study because of other reasons, or any factors judged by investigator that the participants cannot meet.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Itraconazole and SH-1028	SH-1028	In the itraconazole study, patients received single-dose SH-1028 200 mg on Days 1 and 12 and itraconazole(200 mg twice daily) on Days 8-14 orally.
Itraconazole and SH-1028	Itraconazole	In the itraconazole study, patients received single-dose SH-1028 200 mg on Days 1 and 12 and itraconazole(200 mg twice daily) on Days 8-14 orally.
Rifampicin and SH-1028	Rifampicin	In the rifampicin study, patients received SH-1028 200mg once daily on Days 1 and 14 and rifampicin 600 mg once daily on Days 8-16
Rifampicin and SH-1028	SH-1028	In the rifampicin study, patients received SH-1028 200mg once daily on Days 1 and 14 and rifampicin 600 mg once daily on Days 8-16

Primary Outcome Measures

Name	Time	Method
Cmax	Blood samples collected on Day 1 and Day 12 (arm 1)/Day 14 (arm 2) at pre-dose, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 96 hours post SH-1028 dose	Pharmacokinetics of SH-1028 by assessment of maximum plasma concentration
AUC(0-last)	Blood samples collected on Day 1 and Day 12 (arm 1)/Day 14 (arm 2) at pre-dose, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 96 hours post SH-1028 dose	Pharmacokinetics of SH-1028 by assessment of area under the plasma concentration time curve from zero to last assessed timepoint
AUC(0-∞)	Blood samples collected on Day 1 and Day 12 (arm 1)/Day 14 (arm 2) at pre-dose, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 96 hours post SH-1028 dose	Pharmacokinetics of SH-1028 by assessment of area under the concentration time curve from time 0 to infinity

Secondary Outcome Measures

Name	Time	Method
Incidence of adverse events	Up to 10 days after last dose	Safety and tolerability

Trial Locations

Locations (1)

the First Affiliated Hospital with Bengbu Medical College; 🇨🇳 Bengbu, Anhui, China